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Background:  Epicardial  adipose  tissue  (EAT)  surrounding  the  heart  may  contribute  to  the  development
of  coronary  artery  disease  (CAD)  through  its local  secretion  of  adipocytokines.  Although  the  quantity  of
EAT is  associated  with  obesity  and metabolic  syndrome,  the  role of  EAT  in  the  development  of  CAD in
non-obese  patients  remains  to be determined.
Methods:  This study  included  41  patients  with  CAD  who  underwent  coronary  artery  bypass  graft  surgery
and  28  patients  without  CAD  who  underwent  other  cardiac  surgery.  EAT  volume  was  measured  by 64-slice
multi-detector  computed  tomography  before  the  surgery.  We  obtained  pericardial  ﬂuid  and  epicardial
and  subcutaneous  adipose  tissue  samples  at the  surgery.  We  investigated  the relationship  between  EAT
volume  and  adiponectin  levels  in  pericardial  ﬂuid  and  incident  CAD  in patients  with  and  without  obesity
(body  mass  index  >  25  kg/m2).
Results:  There  was  no  signiﬁcant  difference  in EAT  volume  between  obese  patients  with  and  without
CAD  (55.5  ± 40.2  mL  vs.  40.1  ±  19.7 mL, p =  0.323).  However,  EAT  volume  was  signiﬁcantly  greater  in non-
obese  patients  with  CAD  compared  to those  without  CAD  (35.0  ±  18.8  mL  vs. 15.7 ±  11.0 mL,  p  <  0.001).
Adiponectin  concentrations  in  pericardial  ﬂuid  were  signiﬁcantly  lower  in  non-obese  patients  with CAD
compared  to those  without  CAD  (2.7 ± 2.0  g/mL  vs. 4.3  ±  3.7 g/mL, p = 0.049),  whereas  the  adiponectin
levels were  decreased  in  obese  patients  regardless  of the  presence  of  CAD.  Non-obese  patients  with  CAD
had signiﬁcantly  larger  size  adipocytes  in EAT  but not  subcutaneous  adipose  tissue  compared  to  those
without  CAD.  Multiple  logistic  regression  analysis  showed  that  increased  EAT  volume  was  independently
associated  with  incident  CAD  in  non-obese  patients.
Conclusion: Increased  EAT may  play  a crucial  role  in  development  of  CAD  through  impairment  of
adiponectin  secretion  in non-obese  patients.
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ntroductionObesity or excess body fat is a well-established risk factor
or cardiovascular diseases [1,2]. Increased visceral fat causes
nsulin resistance, which promotes atherosclerosis [3–5]. Recently,
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accumulation of epicardial adipose tissue (EAT) was  reported to
be associated with incidence of coronary artery disease (CAD)
[6–9]. EAT produces a number of cytokines involved in the devel-
opment of atherosclerosis, including tumor necrosis factor-alpha
(TNF-), interleukin-6 (IL-6), plasminogen activator inhibitor-1,
as well as adipocytokines, such as adiponectin [10–14]. A low
plasma adiponectin level is an independent predictor of cardiovas-
cular diseases [14,15]. These ﬁndings suggest that EAT surrounding
the coronary arteries may  inﬂuence the progression of coronary
atherosclerosis. In addition, the inﬂuence of pericardial fat on the
development of CAD may  differ between obese and non-obese
vier Ltd. All rights reserved.
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ubjects [8]. Although obesity and metabolic syndrome relate to
he amount of EAT [16], the role of EAT in the development of CAD
n non-obese patients remains to be fully determined.
In this cross-sectional study, we examined the relationship
etween EAT volume, as quantiﬁed by multi-detector computed
omography (MDCT), and incidence of severe CAD in obese and
on-obese patients who underwent cardiac surgery. Further, we
nvestigated whether adiponectin levels in pericardial ﬂuid are
ssociated with EAT volume and incident CAD.
ethods
tudy subjects
The study population consisted of 41 patients with severe
AD who underwent coronary artery bypass graft surgery, and
8 patients without CAD who underwent other cardiac surgery and
howed no coronary calciﬁcation and stenosis which was evalu-
ted by invasive angiography between December 2005 and May
009. Among the patients without CAD, 20 had valvular heart
isease, 4 had thoracic aortic aneurysms, and 4 had other con-
itions. The exclusion criteria were New York Heart Association
NYHA) class III or IV heart failure and known hypersensitivity to
odine-based contrast agents. Obesity was deﬁned as a body mass
ndex (BMI) > 25 kg/m2. Clinical information was obtained from the
atients’ medical records. Blood samples were obtained from all
atients at admission. Fasting glucose levels, glycated hemoglobin
1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), high-
ensity lipoprotein cholesterol (HDL-C), and triglycerides (TG)
ere measured using routine laboratory techniques. Hyperten-
ion was deﬁned as systolic blood pressure ≥ 140 mmHg  and/or
iastolic pressure ≥ 90 mmHg, or current use of antihyperten-
ive drugs. Diabetes mellitus was deﬁned as a fasting plasma
lucose concentration of ≥126 mg/dL, HbA1c (JDS) ≥ 6.5%, or cur-
ent use of insulin or hypoglycemic agents. Dyslipidemia was
eﬁned as LDL-C ≥ 140 mg/dL, TG ≥ 150 mg/dL, HDL-C < 40 mg/dL,
r current use of antihyperlipidemic drugs. Metabolic syndrome
as evaluated using the US National Cholesterol Education Pro-
ram Adult Treatment Panel III (NCEP/ATPIII) criteria [17]. The
CEP/ATPIII criteria for abdominal obesity were modiﬁed by using
MI  ≥ 25 kg/m2 instead of the waist circumference because obesity
s deﬁned as BMI  ≥ 25 kg/m2 in Japan [18]. Metabolic syndrome
as deﬁned on the basis of meeting at least 3 of the following
 NCEP/ATPIII criteria: BMI  ≥ 25 kg/m2, elevated TG (≥150 mg/dL)
nd/or reduced HDL-C (<40 mg/dL), elevated blood pressure
ig. 1. Measurement of EAT volume. (A) Manual tracing of ROI containing both heart and
ark  red areas indicate EAT images ranging from −200 to −30 HU isolated from heart im
ccount of interslice gap automatically by analysis software. ROI, region of interest; EAT, iology 63 (2014) 344–349 345
(systolic blood pressure ≥ 130 and/or diastolic blood pressure ≥ 85),
and elevated fasting plasma glucose (≥110 mg/dL). Smoking habit
was self-reported. Informed consent was obtained from all patients
prior to participation in the study, and the protocol was  approved
by the Human Investigations Committee at our institution.
Measurement of epicardial adipose tissue
Cardiac MDCT was  performed using a 64-slice MDCT scanner
(Aquilion 64, Toshiba, Tokyo, Japan). Nitroglycerin was adminis-
tered orally before the CT scan was performed. A total of 51–100 mL
of contrast media (Iopamidol, Bayer Co. Ltd., Leverkusen, Germany)
was injected at a ﬂow rate of 3.0–4.6 mL/s depending on the
patient’s body weight. The region of interest (ROI) was placed
within the ascending aorta and descending aorta, and scanning was
commenced when the CT density reached 250 Hounsﬁeld units
(HU) at the ascending aorta or 180 HU at the descending aorta.
The scan was performed between the tracheal bifurcation and the
diaphragm. Radiographic factors were collimation width 0.5 mm,
rotation speed 0.4 s/rotation, tube voltage 120 kV, and effective
tube current 400–450 mA.  Cardiac images were analyzed at the
most motionless phase of the cardiac cycle, which was  most fre-
quently the mid-diastolic phase, with retrospective cardiac gating
at 75% of the RR interval.
EAT was deﬁned as the adipose tissue between the surface of
the heart and the visceral layer of the pericardium. After manually
tracing a single ROI containing heart and EAT on cross sectional
images, EAT image ranging from −200 to −30 HU was  isolated by
extraction from heart image. EAT area was  measured every 5 mm
thick from the atrial appendage to the apex over the diaphragm. EAT
volume was automatically calculated as the sum of the EAT areas
using analysis software (ZIO station, ZIO SOFT Inc., Tokyo, Japan) as
shown in Fig. 1.
Collection of pericardial ﬂuid, epicardial and subcutaneous
adipose tissue samples
Pericardial ﬂuid and biopsy samples from EAT and subcutaneous
adipose tissue were obtained after median sternotomy and section
of the pericardium in patients who underwent cardiac surgery. EAT
biopsies were harvested near the proximal tract of the right coro-
nary artery. Subcutaneous adipose tissue samples were obtained
from thorax. All tissues were immediately frozen at −80 ◦C.
 EAT on cross sectional computed tomography images from top to bottom of heart.
ages. (B) 3D image of EAT volume calculated as the sum of the EAT areas taking
epicardial adipose tissue.
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easurement of adiponectin concentration in pericardial ﬂuid
Pericardial ﬂuid adiponectin concentrations were measured by
olid phase enzyme linked immunosorbent assay (ELISA), using
 commercially available kit (Otsuka Pharmaceutical Co., Tokyo,
apan).
mmunohistochemistry
Sections of EAT and subcutaneous adipose tissue from non-
bese patients with or without CAD were parafﬁn-embedded,
ewaxed and rehydrated. Slides were incubated overnight with the
rimary anti-adiponectin antibody (1:250 dilution, IMGENEX, San
iego, CA, USA) followed by incubation with avidin biotinylated
eroxidase complex (Promega, Tokyo, Japan). Staining was  visual-
zed by a treatment with 3,3′-diaminobenzidine tetrahydrochloride
olution (Dako, Kyoto, Japan). For negative controls the primary
ntibody was omitted. The area occupied by adipocytes was  mea-
ured by computerized planimetry using Image J software, version
.38x (National Institutes of Health, Bethesda, MD,  USA).
tatistical analysis
Data are presented as mean ± standard deviation (SD) for con-
inuous variables and as percentages of the total number of patients
or categorical variables. Unpaired Student’s t test and chi-square
est were used for comparisons of continuous and categorical
ariables, respectively. Simple correlation between EAT and other
linical parameters was examined using Pearson’s correlation coef-
cient. Logistic regression analysis was performed to identify
igniﬁcant predictors for CAD. Predictors that were signiﬁcant by
nivariate analysis were entered into the multivariate analysis.
djusted multivariate odds ratios were presented with 95% con-
dence intervals. All p-values were two-sided and p-values < 0.05
ere considered signiﬁcant. Statistical analysis was  performed
sing StatView, version 5.0 (SAS Institute Inc., Cary, NC, USA).
able 1
aseline Clinical Characteristics in Patients.
All patients (n = 69) Obese 
CAD (+) (n = 14) 
Age, years 65 ± 11 67 ± 11 
Male,  n (%) 50 (72) 10 (71) 
Body  mass index, kg/m2 23.5 ± 3.7 28.2 ± 2.3 
Systolic blood pressure (mmHg) 124.0 ± 16.5 133.1 ± 20.8 
Diastolic blood pressure (mmHg) 70.8 ± 12.4 71.7 ± 12.1 
Risk  factor
Hypertension, n (%) 53 (77) 13 (93) 
Dyslipidemia, n (%) 50 (72) 11 (79) 
Diabetes mellitus, n (%) 22 (32) 5 (38) 
Smoking, n (%) 32 (46) 10 (71) 
Metabolic syndrome (%) 19 (28) 9 (64) 
Laboratory data
FPG (mg/dL) 111.2 ± 33.1 104.8 ± 20.2 
HbA1c (%) 5.7 ± 0.8 6.1 ± 1.0 
HDL-cholesterol (mg/dL) 43.8 ± 12.9 43.9 ± 14.6 
LDL-cholesterol (mg/dL) 108.4 ± 31.1 115.9 ± 34.0 
Triglyceride (mg/dL) 122.0 ± 73.9 156.1 ± 92.6 
EAT  volume (ml) 34.1 ± 26.8 55.5 ± 40.2 
Pericardial ﬂuid adiponectin (g/ml) 3.2 ± 2.6 2.9 ± 1.8 
Medications, n (%)
ACE inhibitors and/or ARBs 47 (68) 11 (79) 
  blockers 21 (30) 5 (36) 
Ca  channel blockers 33 (48) 9 (64) 
Antiplatelets 40 (58) 12 (86) 
Statins 35 (51) 7 (50) 
ata are presented as mean ± SD or % unless otherwise indicated. CAD, coronary artery
ipoprotein; LDL, low density lipoprotein; EAT, epicardial adipose tissue; ACE, angiotensiniology 63 (2014) 344–349
Results
Clinical characteristics of study patients
There were no signiﬁcant differences in the clinical character-
istics between obese patients with and without CAD (Table 1). The
prevalence of hypertension, dyslipidemia, and smoking was higher
in non-obese patients with CAD than in those without CAD. HbA1c
levels were higher in non-obese patients with CAD compared to
those without CAD. There were 19 patients who had metabolic
syndrome. The prevalence of metabolic syndrome was not differ-
ent between patients with and without CAD (Table 1). Non-obese
patients with CAD had higher use of calcium channel blockers,
antiplatelet drugs, and statins compared to those without CAD.
EAT volume in patients with and without CAD
Non-obese patients with CAD had a signiﬁcantly larger EAT
volume compared to those without CAD. Whereas there was no sig-
niﬁcant difference in EAT volume between obese patients with and
without CAD (Table 1). EAT volume correlated to age, BMI, and LDL-
C in all patients (Table 2). However, BMI  correlated with EAT volume
in obese patients but not in non-obese patients. Interestingly EAT
volume correlated with LDL-C levels in non-obese patients.
Adiponectin concentration in pericardial ﬂuid
There was no difference in adiponectin levels in pericardial ﬂuid
between obese patients with and without CAD because adiponectin
levels were similarly decreased in both groups (Table 1). In contrast,
non-obese patients with CAD showed signiﬁcantly lower levels of
adiponectin compared to those without CAD (Table 1). There was
an inverse correlation between EAT volume and adiponectin levels
in pericardial ﬂuid in non-obese patients, but not obese patients
(Table 2).
p-Value Non-obese p-Value
CAD (−) (n = 8) CAD (+) (n = 27) CAD (−) (n = 20)
68 ± 10 0.784 66 ± 10 62 ± 12 0.195
5 (63) 0.667 21 (78) 14 (70) 0.545
26.5 ± 1.3 0.078 22.5 ± 1.9 20.3 ± 2.5 0.001
128.8 ± 18.8 0.627 122.3 ± 11.6 118.1 ± 15.8 0.298
73.1 ± 10.4 0.786 72.7 ± 11.1 66.5 ± 14.5 0.101
7 (88) 0.674 24 (89) 9 (45) 0.001
7 (88) 0.601 22 (81) 10 (50) 0.022
2 (25) 0.604 10 (37) 5 (25) 0.381
4 (50) 0.315 14 (52) 4 (20) 0.026
4 (50) 0.512 5 (19) 1 (5) 0.170
100.5 ± 16.4 0.681 116.8 ± 37.9 110.9 ± 35.4 0.613
5.9 ± 0.8 0.665 5.7 ± 0.7 5.3 ± 0.8 0.048
38.0 ± 10.1 0.386 42.9 ± 12.2 46.7 ± 13.6 0.322
138.2 ± 25.5 0.169 105.2 ± 33.5 98.6 ± 20.8 0.443
143.3 ± 33.8 0.731 122.2 ± 82.9 92.0 ± 43.3 0.145
40.1 ± 19.7 0.323 35.0 ± 18.8 15.7 ± 11.0 <0.001
3.0 ± 2.5 0.911 2.7 ± 2.0 4.3 ± 3.7 0.049
2 (25) 0.014 21 (78) 13 (65) 0.333
2 (25) 0.604 7 (26) 7 (35) 0.501
5 (63) 0.933 16 (59) 3 (15) 0.002
2 (25) 0.004 19 (70) 7 (35) 0.016
3 (38) 0.571 21 (78) 4 (20) <0.001
 disease; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high density
-converting enzyme; ARB, angiotensin receptor blocker.
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Table  2
Correlation of epicardial adipose tissue volume with clinical parameters.
All patients Obese patients Non-obese patients
R p-Value R p-Value R p-Value
Age (year) 0.247 0.041 0.393 0.071 0.087 0.562
Body  mass index (kg/m2) 0.503 <0.001 0.460 0.031 0.269 0.067
Systolic blood pressure (mmHg) 0.102 0.402 0.159 0.481 0.130 0.385
Diastolic blood pressure (mmHg) 0.017 0.889 0.149 0.509 0.078 0.602
FPG  (mmHg) 0.173 0.212 0.163 0.595 0.144 0.368
HbA1c (%) 0.025 0.847 0.204 0.418 0.010 0.948
HDL-cholesterol (mg/dL) 0.032 0.796 0.335 0.149 0.142 0.343
LDL-cholesterol (mg/dL) 0.292 0.017 0.057 0.810 0.341 0.019
Triglyceride (mg/dL) 0.171 0.166 0.104 0.664 0.239 0.105
F ; LDL
A
s
d
n
(
a
v
s
f
(
F
a
aPericardial ﬂuid adiponectin (g/ml) 0.209 0.084 
PG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high density lipoprotein
diponectin expression and adipocyte size in EAT and
ubcutaneous adipose tissue in non-obese patients
Representative images of immunohistochemical staining
emonstrated a greater expression of adiponectin in EAT in
on-obese patients without CAD compared to those with CAD
Fig. 2A and B). Non-obese patients with CAD had a larger
dipocyte size in EAT than those without CAD (14,547 ± 2276 m2
s. 9677 ± 3141 m2, p = 0.014) (Fig. 2D). However, adipocyte
ize in subcutaneous adipose tissue was not signiﬁcantly dif-
erent between non-obese patients with and without CAD
2 214,791 ± 1901 m vs. 12,069 ± 5136 m , p = 0.5612) (Fig. 2E).
ig. 2. Representative images of immunohistochemical staining of adiponectin in EAT in
ntibodies of adiponectin. Original magniﬁcation ×200. Scale bars, 100 m. Comparison o
nd  CAD groups. EAT, epicardial adipose tissue; CAD, coronary artery disease.0.063 0.780 0.312 0.033
, low density lipoprotein.
Impact of EAT volume on incident CAD in patients with and
without obesity
Although there were no signiﬁcant predictors for incident
CAD in obese patients in univariate logistic regression anal-
ysis (Table 3), BMI, EAT volume, hypertension, dyslipidemia,
and smoking were signiﬁcantly associated with incident CAD in
non-obese patients. Metabolic syndrome was not signiﬁcantly
associated with incident CAD in univariate logistic regression anal-
ysis (Table 3). Multivariate analysis revealed that EAT volume was
signiﬁcantly associated with incident CAD in non-obese patients
(Table 3).
 non-obese patients. (A) A non-CAD patient, (B) CAD, (C) negative control without
f adipocyte size in EAT (D) and subcutaneous adipose tissue (E) between non-CAD
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Table  3
Logistic regression analysis with CAD in patients.
Obese Univariate analysis
OR 95% CI p-Value
Age (per 1-year increase) 0.99 0.91–1.08 0.636
Male  gender 1.50 0.24–9.47 0.666
Body  mass index (per 1-kg/m2) 1.76 0.89–3.47 0.104
EAT  (per 1SD mL  increase) 1.79 0.55–5.92 0.323
Adiponectin (per 1 g/ml increase) 0.97 0.63–1.51 0.905
Presence of
Hypertension 1.86 0.10–34.45 0.678
Dyslipidemia 0.52 0.05–6.09 0.606
Diabetes mellitus 1.67 0.24–11.58 0.605
Smoking 2.50 0.41–15.23 0.320
Metabolic syndrome 1.80 0.31–10.52 0.514
Non-obese Univariate analysis Multivariate analysis
OR 95% CI p-Value OR 95% CI p-Value
Age (per 1-year increase) 1.04 0.98–1.10 0.193
Male  gender 1.50 0.40–5.61 0.547
Body mass index (per 1-kg/m2) 1.59 1.15–2.18 0.005 1.52 0.99–2.35 0.057
EAT  (per 1SD mL  increase) 10.13 2.51–41.00 0.001 8.27 1.12–61.60 0.039
Adiponectin (per 1 g/ml increase) 0.80 0.63–1.02 0.066
Presence of
Hypertension 9.78 2.21–43.34 0.003 3.71 0.37–37.46 0.267
Dyslipidemia 4.40 1.19–16.28 0.026 3.63 0.47–28.03 0.217
Diabetes mellitus 1.77 0.49–6.34 0.383
Smoking 4.31 1.14–16.30 0.031 9.90 0.98–100.03 0.052
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AD, coronary artery disease; OR, odds ration; CI, conﬁdence interval; EAT, epicard
iscussion
In the present study, non-obese patients with severe CAD
howed increased EAT volume and decreased adiponectin secreted
n pericardial ﬂuid, whereas obese patients with CAD did not.
diponectin levels in pericardial ﬂuid correlated with EAT volume
n non-obese patients. Increased adipocyte size was  observed in
AT but not in subcutaneous adipose tissue in non-obese patients
ith CAD. Our results suggested that increased EAT volume and
dipocyte size are associated with impairment of adiponectin
ecretion, which may  cause incident CAD.
Although several studies reported that increased EAT is a risk
actor of CAD, standardized method of quantiﬁcation of EAT has
ot yet been established [19,20].
The quantiﬁcation of EAT with echocardiography is inferior to
hat with MDCT, since echocardiography cannot give an adequate
indow of all cardiac segments and measurement of EAT may  be
naccurate due to lower resolution of echocardiography [21–23].
everal reports showed that EAT thickness measured by 64-MDCT
as associated with metabolic syndrome [16,24]. However, EAT
hickness does not necessarily correlate with metabolic syndrome
16,25]. It was also demonstrated that EAT volume measured by
4-MDCT was highly reproducible compared to EAT thickness and
eri-coronary fat thickness [16,26].
Whereas EAT volume correlated with BMI  in obese patients,
here was no correlation between EAT volume and BMI in non-
bese patients. On the other hand, EAT volume correlated with
DL-C levels in non-obese patients but not in obese patients. Obese
atients had higher LDL-C levels and EAT volume than non-obese
atients regardless of the presence of CAD. Previous reports showed
hat EAT volume was associated with incident CAD independently
f BMI  [7,8]. It was reported that EAT volume is negatively corre-
ated with adiponectin expression in EAT [27]. EAT was reported
o be a source of pro-inﬂammatory mediators [13] and polarize
acrophages toward inﬂammatory subtype [28], which contribute
o the development of CAD. Recently, an interesting concept termed
he outside-to-inside hypothesis has been advanced, that vascular0.199
pose tissue; SD, standard deviation.
inﬂammation is initiated in the adventitia and progresses inward
to the intima [29]. In fact, decreased adiponectin levels in both EAT
and pericardial ﬂuid were observed in non-obese patients with CAD
in the present study. Furthermore, in non-obese patients adipocyte
size in EAT with CAD was  larger than those without CAD and EAT
volume was  signiﬁcantly correlated with LDL-C. A previous study
showed that adipocyte size is positively correlated with LDL-C lev-
els [30]. These results may  suggest that adipocyte hypertrophy is
associated with LDL-C, which contributes to the development of
CAD. Enlarged EAT may  exhibit impaired adiponectin secretion,
which is associated with development of atherosclerosis. It was
also reported that adipocyte size in EAT is positively associated with
insulin resistance and negatively associated with adiponectin gene
expression [31]. These results suggested that as adipocytes become
larger, their secretory proﬁle may  change toward a more inﬂam-
matory phenotype. On the other hand, since adiponectin secretion
from enlarged EAT was  impaired in obese patients, there was  no dif-
ference in adiponectin levels in pericardial ﬂuid between patients
with and without CAD. Therefore, it was  thought that increased EAT
volume could not predict incident CAD in obese patients. Increased
EAT may  be a feasible predictor of development of CAD especially
in non-obese patients.
The present study had several limitations. There might be selec-
tion bias since we enrolled the patients undergoing cardiac surgery
to obtain the pericardial ﬂuid and EAT. Since a relatively small
number of obese patients participated in the present study, there
was the possibility that EAT volume was not a signiﬁcant predictor
of incident CAD in obese patients. Since there was  no correlation
between incident CAD and cytokines in pericardial ﬂuid such as IL-
6 and TNF- in the preliminary test (data not shown), we did not
measure such cytokines in all patients.
ConclusionsIncreased EAT volume was  an independent risk factor of incident
CAD in non-obese patients. Adiponectin levels in pericardial ﬂuid
were decreased with increasing EAT volume in non-obese patients
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